Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the sage domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/wp1_php82fpm/offhealth/web/wp/wp-includes/functions.php on line 6131
{"id":2094,"date":"2024-04-09T10:19:30","date_gmt":"2024-04-09T10:19:30","guid":{"rendered":"https:\/\/offhealth.netseven.work\/ricerca\/clinical-efficacy-tolerability-and-safety-of-a-new-multiple-action-eyedrop-in-subjects-with-moderate-to-severe-dry-eye\/"},"modified":"2024-05-14T13:47:42","modified_gmt":"2024-05-14T13:47:42","slug":"clinical-efficacy-tolerability-and-safety-of-a-new-multiple-action-eyedrop-in-subjects-with-moderate-to-severe-dry-eye","status":"publish","type":"ricerca","link":"https:\/\/offhealth.netseven.work\/en\/ricerca\/clinical-efficacy-tolerability-and-safety-of-a-new-multiple-action-eyedrop-in-subjects-with-moderate-to-severe-dry-eye\/","title":{"rendered":"Clinical Efficacy, Tolerability and Safety of a New Multiple-Action Eyedrop in Subjects with Moderate to Severe Dry Eye"},"content":{"rendered":"\n

Introduction<\/h4>\n\n
Dry eye disease (DED) represents one of the most common eye disorders, with a reported prevalence rate ranging from 5 to 50 percent and peaking after the fifth decade of life. It has been identified as a disorder of the Lacrimal Functional Unit (LFU), an integrated system including lacrimal glands, ocular surface, eyelids, and sensory and motor nerves. <\/p>\n\n
Resulting in significant morbidity, DED has a significant impact on patients’ visual function and quality of life. \nDED can present clinically with mild to severe ocular discomfort associated with signs and symptoms of varying intensity and visual acuity impairment.<\/p>\n\n
In this prospective observational cohort study, 41 subjects with moderate to severe dry eye were enrolled and divided into two groups. Group 1 was treated with TriMix\u00ae and group 2 was treated with 3% Trehalose four times daily for 2 months. All subjects were evaluated at baseline (V0) and at day 60 \u00b1 3 (V1). Assessment included at each follow-up measurement of best corrected visual acuity (BCVA), assessment of symptom frequency and intensity by questionnaire (SANDE), osmolarity, fluorescein tear film break-up time (TBUT), and corneal and conjunctival staining with fluorescein; assessment of the presence\/absence of erythema and edema of the eyelids, conjunctival chemosis, and hyperemia was also performed.<\/p>\n\n